(Q24235249)

7

0 references

Roberto D'Amico

4

0 references

Cinzia Del Giovane

2

0 references

Carlo Di Pietrantonj

5

0 references

Deirdre Beecher

6

0 references

author name string

Laura Vacchi

Cochrane Database of Systematic Reviews

3

0 references

publication date

19 January 2011

0 references

published in

0 references

cites work

Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Simultaneous comparison of multiple treatments: combining direct and indirect evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Disability as an outcome in MS clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Mechanism of action of mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Indirect comparisons of competing interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Borrowing strength from external trials in a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Combination of direct and indirect evidence in mixed treatment comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Multiple sclerosis: Geoepidemiology, genetics and the environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Corticosteroids treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Evaluation of networks of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

The mechanism of action of methylprednisolone in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Bayesian measures of model complexity and fit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008933